BiotechTube

ARD-101

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

May 27, 2022 → Sep 24, 2024

NCT ID
NCT05153434

About ARD-101

ARD-101 is a phase 2 stage product being developed by Aardvark Therapeutics for Prader-Willi Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05153434. Target conditions include Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT07197034Phase 3Active
NCT05153434Phase 2Completed
NCT05215847Phase 2Completed

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Octreotide + PlaceboNovartisPre-clinical
23
Norditropin SimpleXxNovo NordiskPre-clinical
22
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
76
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
49
SetmelanotideRhythm PharmaceuticalsPhase 2
49
RGH-706 + PlaceboRichter GedeonPhase 2
49
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
DCCRSoleno TherapeuticsPhase 3
72
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
PitolisantHarmony BiosciencesPhase 3
72
Pitolisant tabletHarmony BiosciencesPhase 3
72
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
47
DCCRSoleno TherapeuticsPhase 3
72
VYKAT XRSoleno TherapeuticsPre-clinical
18
DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
NNZ-2591Neuren PharmaceuticalsPhase 2
47
BMB-101 + PlaceboBright Minds BiosciencesPhase 2
47

Other Products from Aardvark Therapeutics

Placebo + ARD-101Phase 3
69
ARD-101Phase 3
69
Low Dose ARD-501 + High Dose ARD-501 + PlaceboPhase 2
44
ARD-101Phase 2
44
ARD-101 + PlaceboPhase 2
44